MedPath

Comparison of the effect of two methods of cabergoline administration to prevent ovarian hyperstimulation syndrome in women with polycystic ovary syndrome

Phase 3
Recruiting
Conditions
Polycystic ovarian syndrome.
Polycystic ovarian syndrome
E28.2
Registration Number
IRCT20090526001952N16
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
200
Inclusion Criteria

Age range of 18 to 45 years old
Patients with polycystic ovary syndrome
high level of anti-müllerian hormone (AMH) level (> 3 ng/ml) and/or high antral follicle count (AFC)>20

Exclusion Criteria

Allergy to cabergoline
Not taking the drug completely
Stopping the drug due to side effects or drug sensitivity

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ovarian hyperstimulation syndrome. Timepoint: Three days after pancture. Method of measurement: Ultrasound and clinical findings.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath